Document Type : Original Article


1 Department of Internal Medicine, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran

2 Department of Infectious Disease and Tropical Medicine, Ardabil University of Medical Science, Ardabil, Iran

3 Social Determinants of Health Research Center, Ardabil University of Medical Sciences, Ardabil, Iran

4 Department of Anesthesiology, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran

5 Department of Microbiology and Immunology, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran

6 Department of Biostatistics, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran


BACKGROUND: Infection with COVID‑19 has resulted in considerable mortality all around the world.
This study aimed to investigate the effect of convalescent plasma on the treatment of hospitalized
patients with COVID‑19 in Imam Khomeini Hospital at Ardabil, Iran.
MATERIALS AND METHODS: In this quasi‑experimental clinical trial, patients over 18 years of age
with polymerase chain reaction‑positive COVID‑19 were admitted based on the clinical criteria of
respiratory distress with hypoxia (O2
 saturation <90) and tachypnea (R Relative Risk (RR) >24) with
moderate‑to‑severe lung involvement and in the 1st week of respiratory disease who were not intubated
were nonrandomly assigned to two groups: convalescent plasma therapy (CPT) group (197 cases)
and control group (200 cases). We used the Chi‑square, t‑test, Fisher’s exact test, and Pearson’s
correlation coefficient for statistical analysis.
RESULTS: Analyses revealed that length of stay in hospital was significantly lower in the CPT group
as compared to the control group (P = 0.001). Twenty‑four cases (22.0%) in the CPT group and
85 cases (78.0%) in the control group needed intubation. Furthermore, mortality was 17 cases (18.3%)
in the CPT group and 76 cases (81.7%) in the control group, the difference of which was also found
to be statistically significant (P < 0.05).
CONCLUSIONS: It seems that CPT can be used as an alternative treatment at the early stages of
COVID‑19 to prevent the progress of the disease, reduce the need for intubation and consequently
the length of stay in hospital, and finally, decrease mortality.


1. Arefi MF, Babaei AP, Barzanouni S, Ebrahimi S, Salehi AR,
Khajehnasiri F, Poursadeghian M. Risk Perception in the
COVID-19 pandemic; a health promotion approach. J Edu Health
Promot 2022;11:118.
2. Soltaninejad M, Babaei‑Pouya A, Poursadeqiyan M, Feiz Arefi M.
Ergonomics factors influencing school education during the
COVID‑19 pandemic: A literature review. Work. 2021;68 (1):69‑75.
3. Khajehnasiri f, zaroushani v, poursadeqiyan m. Macroergonomics
and health workers during Covid‑19 pandemic, Work.
2021;69 (3):713‑714.
4. DargahiA, Jeddi F, Ghobadi H, VosoughiM, Karami C, SarailooM, et al. Evaluation of masks’ internal and external surfaces used by
health care workers and patients in coronavirus‑2 (SARS‑CoV‑2)
wards. Environ Res 2021;196:110948.
5. Poursadeqiyan M, Bazrafshan E, Arefi MF. Review of
environmental challenges and pandemic crisis of Covid-19. J
Edu Health Promot 2020;9:250.
6. Karami C, Normohammadi A, Dargahi A, Vosoughi M,
Zandian H, Jeddi F, et al. Investigation of SARS‑CoV‑2 virus on
nozzle surfaces of fuel supply stations in North West of Iran. Sci
Total Environ 2021;780:146641.
7. Pourfarzi F, Rahim Pouran S, Dargahi A, Karami C, Fouladi N,
Zandian H, Zahirian Moghadam T. The healthy behaviours and
COVID‑19 mortality among Iranian women: a case–control study.
BMC Women’s Health. 2021;21 (1):1‑8.
8. Zandian H, Sarailoo M, Dargahi S, Gholizadeh H, Vosoughi M,
Dargahi A. Evaluation of knowledge and health behavior of
university of medical sciences students about the prevention of
COVID‑19. Work. 2021,68 (3):543‑549.
9. Erfanian N, Miri‑Moghaddam E. Treatment of COVID‑19 patients
using plasma therapy. J Birjand Univ Med Sci 2021;28:84‑7.
10. Lu H. Drug treatment options for the 2019‑new coronavirus
(2019‑nCoV). Biosci Trends 2020;14:69‑71.
11. MaranoG, VaglioS, PupellaS, FaccoG, CatalanoL, LiumbrunoGM,
et al. Convalescent plasma: New evidence for an old therapeutic
tool? Blood Transfus 2016;14:152‑7.
12. Salazar E, Perez KK, Ashraf M, Chen J, Castillo B, Christensen PA,
et al. Treatment of coronavirus disease 2019 (COVID‑19) patients
with convalescent plasma. Am J Pathol 2020;190:1680‑90.
13. Sarailoo M, Matin S, Vosoughi M, Dargahi A, Gholizadeh H,
Rajabi Damavandi M, Abbasi‑Ghahramanloo A, Kamran A.
Investigating the relationship between occupation and
SARS‑CoV2. Work. 2021, 68 (1): 27–32.
14. Focosi D, Anderson AO, Tang JW, Tuccori M. Convalescent
plasma therapy for COVID‑19: State of the art. Clin Microbiol
Rev 2020;33:e00072‑20.
15. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential
therapy for COVID‑19. Lancet Infect Dis 2020;20:398‑400.
16. Budhiraja S, Dewan A, Aggarwal R, Singh O, Juneja D, Pathak S,
et al. Effectiveness of convalescent plasma in Indian patients with
COVID‑19. Blood Cells Mol Dis 2021;88:102548.
17. Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F, et al. Treatment
with convalescent plasma for COVID‑19 patients in Wuhan,
China. J Med Virol 2020;92:1890‑901.
18. Zahirian Moghadam T, Pourfarzi F, Karami C, Rahimpouran S,
Zandian H, Dargahi A. The Effect of Working‑based Individual
Protective Behaviors (WIPB) on COVID‑19 Mortality in
North‑West of Iran: A Case‑Control Study. JOHE. 2021;
10 (3):158‑168.
19. Sahr F, Ansumana R, Massaquoi TA, Idriss BR, Sesay FR,
Lamin JM, et al. Evaluation of convalescent whole blood for
treating Ebola virus disease in Freetown, Sierra Leone. J Infect
20. Van Griensven J, Edwards T, de Lamballerie X, Semple MG,
Gallian P, Baize S, et al. Evaluation of convalescent plasma for
Ebola virus disease in Guinea. N Engl J Med 2016;374:33‑42.
21. Zhao Q, He Y. Challenges of convalescent plasma therapy on
COVID‑19. J Clin Virol 2020;127:104358.
22. Abolghasemi H, Eshghi P, Cheraghali AM, Imani Fooladi AA,
Bolouki Moghaddam F, Imanizadeh S, et al. Clinical efficacy
of convalescent plasma for treatment of COVID‑19 infections:
Results of a multicenter clinical study. Transfus Apher Sci
23. Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T,
Malhotra P, et al. Convalescent plasma in the management of
moderate COVID‑19 in adults in India: Open label phase II
multicentre randomised controlled trial (PLACID Trial). BMJ
24. Alsharidah S, Ayed M, Ameen RM, Alhuraish F, Rouheldeen NA,
Alshammari FR, et al. COVID‑19 convalescent plasma treatment of
moderate and severe cases of SARS‑CoV‑2 infection: Amulticenter
interventional study. Int J Infect Dis 2021;103:439‑46.
25. Ahmad A, Salsabil M, Oliver T. Mortality rates in matched cohort,
pseudo‑randomised and randomised trials of convalescent
plasma given to COVID‑19 patients.medRxiv 2020,3:102955.
26. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of
convalescent plasma therapy in severe COVID‑19 patients. Proc
Natl Acad Sci U S A 2020;117:9490‑6.
27. Gharbharan A, Jordans CC, GeurtsvanKessel C, den HollanderJG,
Karim F, Mollema FP, et al. Convalescent plasma for COVID‑19.
A randomized clinical trial. medRxiv 2020;4 (3):1‑10.
28. Vegivinti CT, Pederson JM, Saravu K, Gupta N, Evanson KW,
Kamrowski S, et al. Efficacy of convalescent plasma therapy for
COVID‑19: A systematic review and meta‑analysis. J Clin Apher
29. Simonovich VA, Burgos Pratx LD, Scibona P, Beruto MV,
Vallone MG, Vázquez C, et al. A randomized trial of convalescent
plasma in COVID‑19 severe pneumonia. N Engl J Med
30. Bikdeli B, Talasaz AH, Rashidi F, Bakhshandeh H, Rafiee F,
Rezaeifar P, et al. Intermediate‑dose versus standard‑dose
prophylactic anticoagulation in patients with COVID‑19 admitted
to the intensive care unit: 90‑day results from the INSPIRATION
Randomized Trial. Thromb Haemost 2021;5, 1485‑2372.
31. Yang AP, Liu JP, Tao WQ, Li HM. The diagnostic and predictive
role of NLR, d‑NLR and PLR in COVID‑19 patients. Int
Immunopharmacol 2020;84:106504.
32. Vafadar Moradi E, Teimouri A, Rezaee R, Morovatdar N,
Foroughian M, Layegh P, e t a l . I n c r e a s e d a g e ,
neutrophil‑to‑lymphocyte ratio (NLR) and white blood cells
count are associated with higher COVID‑19 mortality. Am J
Emerg Med 2021;40:11‑4.